LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

LLY

1,136.41

-0.5%↓

JNJ

238.85

+0.91%↑

ABBV

225.29

+0.05%↑

UNH

407.06

-1.28%↓

MRK

119

-0.38%↓

Kodu・Aktsiate loetelu・Denali Therapeutics Inc
Search

Denali Therapeutics Inc

Suletud

SektorTervishoid

20.57 -1.25

Tugev "osta" hinnang

Hinna uuendus 10. juuni 2026, 19:59 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.22

Max

21.71

Põhinäitajad

By Trading Economics

Sissetulek

102K

-128M

Aktsiakasum

-0.69

Töötajad

507

EBITDA

-9.8M

-135M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+70.76% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2026

Turustatistika

By TradingEconomics

Turukapital

136M

3.1B

Eelmine avamishind

21.82

Eelmine sulgemishind

20.57

Uudiste sentiment

By Acuity

27%

73%

67 / 344 Pingereas Healthcare

Denali Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. juuni 2026, 23:36 UTC

Tulu

Correction to Oracle Reports Higher 4Q Profit Article

DJ

Loe

10. juuni 2026, 23:19 UTC

Kuumad aktsiad

Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies

DJ

Loe

10. juuni 2026, 23:09 UTC

Suurimad hinnamuutused turgudel

PureCycle Technologies Slides on Offerings of Stock and Convertible Notes

DJ

Loe

10. juuni 2026, 23:04 UTC

Tulu

Oracle Reports Higher 4Q Profit on Surging Cloud Revenue -- Update

DJ

Loe

10. juuni 2026, 20:44 UTC

Suurimad hinnamuutused turgudel

Caterpillar Raises Quarterly Dividend 8%

DJ

Loe

10. juuni 2026, 23:49 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Northern Star Should Take No Options Off The Table

DJ

Loe

10. juuni 2026, 23:48 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Reiterates Call For Formal Strategic Review of Northern Star

DJ

Loe

10. juuni 2026, 23:48 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Northern Star Board Must Be Substantially Strengthened Beyond 1 Additional Director

DJ

Loe

10. juuni 2026, 23:47 UTC

Market Talk

Nintendo's Stock Recovery Likely Deferred Without Mario Game -- Market Talk

DJ

Loe

10. juuni 2026, 23:47 UTC

Omandamised, ülevõtmised, äriostud

Elliott: Board Letter Indicates It Doesn't Understand Magnitude of Change Required

DJ

Loe

10. juuni 2026, 23:46 UTC

Omandamised, ülevõtmised, äriostud

Elliott Investment Management: Northern Star Letter Validates Investment Thesis

DJ

Loe

10. juuni 2026, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

10. juuni 2026, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

10. juuni 2026, 23:38 UTC

Market Talk

Nikkei Likely to Fall on Renewed Concerns About Iran Conflict -- Market Talk

DJ

Loe

10. juuni 2026, 23:32 UTC

Market Talk

Oil Rises Amid Escalating Supply-Disruption Fears -- Market Talk

DJ

Loe

10. juuni 2026, 23:20 UTC

Market Talk

Wesfarmers's Bunnings Business Looks Resilient to Macro Headwinds -- Market Talk

DJ

Loe

10. juuni 2026, 22:05 UTC

Market Talk

Correction to Bank of Canada Stays on Hold Market Talk

DJ

Loe

10. juuni 2026, 21:57 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 21:52 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 21:35 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 21:22 UTC

Tulu

Oracle Stock Slides on Increased Capital Spending -- WSJ

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:39 UTC

Market Talk
Tulu

Oracle Needs to Raise Less Capital to Fund Data-Center Buildout -- Market Talk

DJ

Loe

10. juuni 2026, 20:34 UTC

Tulu

Oracle Stock Slides on Mixed Earnings. Software Is an Issue. -- Barrons.com

DJ

Loe

10. juuni 2026, 20:33 UTC

Tulu

This 'Amazon for Travel' Firm Beat Earnings Expectations. The Stock Is Soaring. -- Barrons.com

DJ

Loe

10. juuni 2026, 20:33 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

DJ

Loe

10. juuni 2026, 20:33 UTC

Market Talk
Tulu

Oracle Health Expected to Grow Double-Digits This Fiscal Year -- Market Talk

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Denali Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

70.76% tõus

12 kuu keskmine prognoos

Keskmine 35.5 USD  70.76%

Kõrge 42 USD

Madal 23 USD

Põhineb 13 Wall Streeti analüütiku instrumendi Denali Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

13 ratings

13

Osta

0

Hoia

0

Müü

Põhineb 13 analüütiku instrumendi Denali Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

67 / 344 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,136.41

↓-0.5%

JNJ

Johnson and Johnson

238.85

↑ +0.91%

ABBV

AbbVie Inc

225.29

↑ +0.05%

UNH

UnitedHealth Group Inc

407.06

↓-1.28%

MRK

Merck & Co Inc.

119

↓-0.38%
help-icon Live chat